Novartis raised its sales growth target to 5% a year to 2027, citing demand for innovative medicines following the spin-off of its generics business. The medium-term target, which excludes any currency effects, is mainly driven by six drugs led by Kisqali, the Swiss drugmaker said at a presentation.